期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗Gleevec(STI-571)耐受的Bcr-Abl蛋白酪氨酸激酶抑制剂研究进展 被引量：2

Research development of inhibitors against gleevec(STI-571)-resistant Bcr-Abl protien tyrosine kinase
下载PDF
导出
摘要 综述了抗G leevec(ST I-571)耐受的B cr-A b l蛋白酪氨酸激酶抑制剂的研究进展,主要介绍了PD 166326,BM S-354825,AM N 107和ON 012380四种酪氨酸激酶抑制剂. On research development of inhibitors against Gleevec （STI-571） resistan Bcr-Abl protien tyrosine kinase,four inhibitors BMS354825,AMN107,ON012380 and PD166326 were reviewed in this article.
作者 王立升 于海侠 郭鑫 肖军海 李松
机构地区 广西大学化学化工学院 军事医学科学院毒物药物研究所
出处 《广西大学学报（自然科学版）》 CAS CSCD 2006年第1期10-14,48,共6页 Journal of Guangxi University（Natural Science Edition）
关键词 Gleevec(STI-571) Bcr-Abl蛋白酪氨酸激酶 抑制剂 review Gleevec（ST1-571） Bcr-Abl protien tyrosine kinase inhibitors
分类号 R914.4 [医药卫生—药物化学]
  • 相关文献

参考文献32

  • 1郭晓宁,丁健.首个酪氨酸激酶抑制剂药物Gleevec[J].生理科学进展,2003,34(2):183-186. 被引量：6
  • 2高蕾.酪氨酸激酶抑制剂STI571治疗慢性髓细胞白血病[J].国外医学（输血及血液学分册）,2002,25(6):502-504. 被引量：1
  • 3刘芳,骆云鹏,高小平.酪氨酸蛋白激酶抑制剂——Gleevec的抗肿瘤作用[J].中国医院用药评价与分析,2004,4(2):120-122. 被引量：4
  • 4Julia M Brain,Anuraag Saksena,Pierre Laneuville.The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190 Bcr-Abl transgenic mice[J].Leukemia Research,2002,26:1 011-1 016.
  • 5Isabelle Gaston,Paula E Stenberg,Arun Bhat,et al.Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells[J].Experimental Hematology,2000,28:77-86.
  • 6Michael E O'Dwayer,Brian J Druker.STI571:an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia[J].Lancet Oncol,2000,(1):207-211.
  • 7Anjali S Advani,Ann Marie Pendergast.Bcr-Abl variants:biological and clinical aspects[J].Leukemia Research,2002,(26):713-720.
  • 8Druker B J,Talpaz M,Rasta D J,et al.Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia[J].The New England Journal of Medicine,2001,344:1 031-1 037.
  • 9Talpaz M,Silver R T,Durker B J,et al.Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia:results of a phase 2 study[J].Blood 2002,99:1 928-1 937.
  • 10Dorothea Gadzicki,Nils von Neuhoff,Doris Steinemann,et al.Bcr-Abl gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib[J].Cancer Genetics and Cytogenetics,2005,159:164-167.

二级参考文献35

  • 1Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta,2001, 1551 : M11-8.
  • 2ODwyer ME, Druker BJ. STI571 : an inhibitor of the BCRABL tyrosine kinase for the treatment of chronic myelogenous leukemia. THE LANCET Oncology, 2000,1 : 207 -211.
  • 3Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.Science, 2000,289 : 1938 - 1942.
  • 4Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med, 1996,2 : 561 -566.
  • 5Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyro sine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 2000,295 : 139 - 145.
  • 6le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia ceils with an ABL kinase inhibitor. J Nail Cancer Inst, 1999,91 : 163 - 168.
  • 7Druker BJ, Sawyers CL, Talpaz M, et al. Phase I trial of a specificabl tyrosine kinase inhibitor, CGP57148B, in interferon refractory chronic myelogenous leukemia patients.Blood, 1998,92 : 252a.
  • 8Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001,293 : 876 - 880.
  • 9Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science, 2001,293(5538) : 2163a.
  • 10Rowley JD. Nature, 1973,243: 290

共引文献29

同被引文献16

  • 1杨发福,郑林禄,季衍卿,郭红玉,林建荣.含席夫碱和酰胺单元的新型双杯[4]芳烃的合成[J].有机化学,2006,26(2):268-270. 被引量：15
  • 2丛航,陶龙玲,余亦华,杨帆,杜莹,薛赛风,陶朱.瓜环对氨基酸的分子识别研究[J].化学学报,2006,64(10):989-996. 被引量：11
  • 3O'BRIEN SG, GUILHOT F, LARSON RA, et al. Imatinib com- pared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [ J ]. N Engl J Med, 2003,348(11) :994 - 1004.
  • 4DRUKER BJ, GUILHOT F, O'BRIEN SG, et al. Five-yearfol- low-up of patients receiving imatinib for chronicmyeloid leukemia [J]. NEnglJMed, 2006,355(23) :2408 -2417.
  • 5PUTTINI M, COLUCCIA AM,BOSCHELLI F,et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against ima- tlnib-resistant Bcr-Abl + neoplastic cells [ J ]. Cancer Res,2006, 66(23) :11314-11322.
  • 6GOLAS JM, ARNDT K, ETIENNE C, et al. SKI-606, a 4-anili- no-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic nayelogcnous leu- kemia cells in culture and causes regression of K562 xenografts in nude mice [ J ]. Cancer Res,2003,63 ( 2 ) : 375 - 381.
  • 7REDAELLI S, PIAZZA R, ROSTAGNO R, et al. Activity of bo- sutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants[ J]. J Clin Oncol,2009,27(3) :469 -471.
  • 8GAMBACORTI-PASSERINI C, LE COUTRE P, MOLOGNI L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis[ J]. Blood Cells Mol Dis, 1997,23 ( 3 ) :380 - 394.
  • 9FDA. Bosutinib [ EB/OL]. ( 2012 - 09 - 04 ). http ://www. ac- cessdata, fda. gov/drugsatfda_docs/label/2012/203341 lbl. pdf.
  • 10CORTES JE,KANTARJIAN HM,BRUMMENDORF TH, et al. Safety and efficacy of bosutinib ( SKI-606 ) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia pa- tients with resistance or intolerance to imatinib [ J ]. Blood,2011, 118(17) :4567 -4576.

引证文献2

二级引证文献2

广西大学学报（自然科学版）
2006年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部